Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteprivacy & cookiesCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Protein Page:
HIF1A (human)
p Phosphorylation
ac Acetylation
me Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
ub Ubiquitylation
sm Sumoylation
ne Neddylation
gl O-GlcNAc
ga O-GalNAc
pa Palmitoylation
ad Adenylation
sn S-Nitrosylation
ca Caspase cleavage
sc Succinylation

Overview
HIF1A a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Binds to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBPB and EP300. Activity is enhanced by interaction with both, NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP. Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia. Interacts with the HIF1A beta/ARNT subunit; heterodimerization is required for DNA binding. Interacts with COPS5; the interaction increases the transcriptional activity of HIF1A through increased stability. Interacts with EP300 (via TAZ-type 1 domains); the interaction is stimulated in response to hypoxia and inhibited by CITED2. Interacts with CREBBP (via TAZ-type 1 domains). Interacts with NCOA1, NCOA2, APEX and HSP90. Interacts (hydroxylated within the ODD domain) with VHLL (via beta domain); the interaction, leads to polyubiquitination and subsequent HIF1A proteasomal degradation. During hypoxia, sumoylated HIF1A also binds VHL; the interaction promotes the ubiquitination of HIF1A. Interacts with SENP1; the interaction desumoylates HIF1A resulting in stabilization and activation of transcription. Interacts (Via the ODD domain) with ARD1A; the interaction appears not to acetylate HIF1A nor have any affect on protein stability, during hypoxia. Interacts with RWDD3; the interaction enhances HIF1A sumoylation. Interacts with TSGA10. Interacts with RORA (via the DNA binding domain); the interaction enhances HIF1A transcription under hypoxia through increasing protein stability. Interaction with PSMA7 inhibits the transactivation activity of HIF1A under both normoxic and hypoxia- mimicking conditions. Interacts with USP20. Interacts with RACK1; promotes HIF1A ubiquitination and proteasome- mediated degradation. Interacts (via N-terminus) with USP19. Under reduced oxygen tension. Induced also by various receptor-mediated factors such as growth factors, cytokines, and circulatory factors such as PDGF, EGF, FGF2, IGF2, TGFB1, HGF, TNF, IL1B, angiotensin-2 and thrombin. However, this induction is less intense than that stimulated by hypoxia. Repressed by HIPK2 and LIMD1. Expressed in most tissues with highest levels in kidney and heart. Overexpressed in the majority of common human cancers and their metastases, due to the presence of intratumoral hypoxia and as a result of mutations in genes encoding oncoproteins and tumor suppressors. 2 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: DNA-binding; Autophagy; Transcription factor
Chromosomal Location of Human Ortholog: 14q23.2
Cellular Component: cytoplasm; cytosol; nuclear speck; nucleoplasm; nucleus; transcription factor complex
Molecular Function: enzyme binding; histone acetyltransferase binding; Hsp90 protein binding; nuclear hormone receptor binding; protein binding; protein heterodimerization activity; protein kinase binding; RNA polymerase II transcription factor activity, enhancer binding; sequence-specific DNA binding; transcription factor activity; transcription factor binding; ubiquitin protein ligase binding
Biological Process: axon transport of mitochondrion; collagen metabolic process; connective tissue replacement during inflammatory response; elastin metabolic process; epithelial to mesenchymal transition; mRNA transcription from RNA polymerase II promoter; oxygen homeostasis; positive regulation of angiogenesis; positive regulation of chemokine production; positive regulation of endothelial cell proliferation; positive regulation of erythrocyte differentiation; positive regulation of glycolysis; positive regulation of hormone biosynthetic process; positive regulation of nitric-oxide synthase activity; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; positive regulation of vascular endothelial growth factor receptor signaling pathway; regulation of gene expression; regulation of transcription from RNA polymerase II promoter in response to oxidative stress; regulation of transcription, DNA-dependent; regulation of transforming growth factor-beta2 production; response to hypoxia; signal transduction; transcription from RNA polymerase II promoter
Reference #:  Q16665 (UniProtKB)
Alt. Names/Synonyms: ARNT interacting protein; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; BHLHE78; Class E basic helix-loop-helix protein 78; HIF-1-alpha; HIF-1alpha; HIF1; HIF1-alpha; HIF1A; hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor); hypoxia-inducible factor 1 alpha isoform I.3; hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor); Hypoxia-inducible factor 1-alpha; Member of PAS protein 1; member of PAS superfamily 1; MOP1; PAS domain-containing protein 8; PASD8
Gene Symbols: HIF1A
Molecular weight: 92,670 Da
Basal Isoelectric point: 5.17  Predict pI for various phosphorylation states
CST Pathways:  Angiogenesis  |  mTOR Signaling  |  Warburg Effect
Protein-Specific Antibodies or siRNAs from Cell Signaling Technology® Total Proteins
Select Structure to View Below

HIF1A

Protein Structure Not Found.
Download PyMol Script
Download ChimeraX Script


STRING  |  cBioPortal  |  Wikipedia  |  Reactome  |  neXtProt  |  Protein Atlas  |  BioGPS  |  Scansite  |  Pfam  |  RCSB PDB  |  Phospho3D  |  Phospho.ELM  |  NetworKIN  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  Ensembl Gene  |  InnateDB


Sites Implicated In
carcinogenesis, altered: S247‑p
cell cycle regulation: S247‑p
cell growth, induced: S668‑p
cell motility, induced: S668‑p
transcription, altered: S641‑p, S643‑p, S696‑p
transcription, induced: S641‑p, S643‑p, T796‑p
transcription, inhibited: S247‑p
activity, induced: S641‑p, S643‑p
activity, inhibited: S247‑p
intracellular localization: S641‑p, S643‑p
molecular association, regulation: S247‑p, S641‑p, S643‑p
protein degradation: S576‑p, S657‑p
protein stabilization: S641‑p, S643‑p, S668‑p, S687‑p, S696‑p

Modification Sites and Domains Show Modification Legend
Click here to view phosphorylation modifications only

Modification Sites in Parent Protein, Orthologs, and Isoforms Show Modification Legend
 

Show Multiple Sequence Alignment



 LTP 

LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 HTP 

HTP: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
1 0 K10‑ac GAGGANDkkkISSER
0 1 K10‑sm GAGGANDkkkISSER
1 0 K11‑ac AGGANDkkkISSERR
1 0 K12‑ac GGANDkkkISSERRk
1 0 K19‑ac kISSERRkEkSRDAA
1 0 K21‑ac SSERRkEkSRDAARS
1 0 S31‑p DAARSRRskESEVFY
0 1 K32‑ub AARSRRskESEVFYE
1 0 T63‑p KASVMRLtISyLRVR
0 2 Y66‑p VMRLtISyLRVRkLL
0 1 K71‑ub ISyLRVRkLLDAGDL
0 1 I80 LDAGDLDIEDDMKAQ
0 1 S113‑p DGDMIYIsDNVNKYM
0 1 K185‑ub RGRTMNIkSATWKVL
0 1 K185‑sm RGRTMNIkSATWKVL
1 0 S247‑p KTFLSRHsLDMKFSY
0 1 K289‑ub LDSDHLTkTHHDMFT
0 1 K297‑ub THHDMFTkGQVTTGQ
0 1 K377‑ub KMTQLFTkVESEDTS
1 0 K389‑ac DTSSLFDkLkKEPDA
0 1 K389‑ub DTSSLFDkLkKEPDA
0 1 K391‑ub SSLFDkLkKEPDALT
1 1 K391‑sm SSLFDkLkKEPDALT
0 4 S451‑p QNINLAMsPLPtAEt
1 1 T455‑p LAMsPLPtAEtPKPL
0 1 T458‑p sPLPtAEtPKPLRSs
1 0 S465‑p tPKPLRSsADPALNQ
0 1 K477‑ub LNQEVALkLEPNPES
1 0 K477‑sm LNQEVALkLEPNPES
5 0 K532‑ac SDMVNEFkLELVEkL
3 0 K532‑ub SDMVNEFkLELVEkL
1 3 K538‑ub FkLELVEkLFAEDTE
1 0 K547‑ub FAEDTEAkNPFSTQD
0 1 T555‑p NPFSTQDtDLDLEML
0 1 Y565‑p DLEMLAPyIPMDDDF
1 0 S576‑p DDDFQLRsFDQLSPL
3 2 S641‑p DIKILIAsPsPTHIH
3 5 S643‑p KILIAsPsPTHIHKE
0 1 T645 LIAsPsPTHIHKEtt
0 1 T651‑p PTHIHKEttsATssP
0 1 T652‑p THIHKEttsATssPY
0 3 S653‑p HIHKEttsATssPYR
0 1 S656‑p KEttsATssPYRDTQ
1 1 S657‑p EttsATssPYRDTQS
1 1 S668‑p DTQSRTAsPNRAGkG
2 0 K674‑ac AsPNRAGkGVIEQTE
0 1 K674‑ub AsPNRAGkGVIEQTE
1 5 S687‑p TEKSHPRsPNVLsVA
1 0 S692‑p PRsPNVLsVALsQRT
1 1 S696‑p NVLsVALsQRTtVPE
1 0 T700‑p VALsQRTtVPEEELN
2 0 K709‑ac PEEELNPkILALQNA
0 1 K709‑ub PEEELNPkILALQNA
1 0 S727‑p RKMEHDGsLFQAVGI
1 0 S760‑p KRVKGCKssEQNGME
1 0 S761‑p RVKGCKssEQNGMEQ
1 0 T796‑p ESGLPQLtSYDCEVN
1 0 S809‑p VNAPIQGsRNLLQGE
  mouse

 
K10 GAGGENEKKKMSSER
K10 GAGGENEKKKMSSER
K11 AGGENEKKKMSSERR
K12 GGENEKKKMSSERRK
K19 KMSSERRKEKSRDAA
K21 SSERRKEKSRDAARS
S31 DAARSRRSKESEVFY
K32 AARSRRSKESEVFYE
T63 KASVMRLTISyLRVR
Y66‑p VMRLTISyLRVRKLL
K71 ISyLRVRKLLDAGGL
S80‑p LDAGGLDsEDEMKAQ
S113 DGDMVYISDNVNKYM
K185 RGRTMNIKSATWKVL
K185 RGRTMNIKSATWKVL
S247 KTFLSRHSLDMKFSY
K289 LDSDHLTKTHHDMFT
K297 THHDMFTKGQVTTGQ
K377 KMTQLFTKVESEDTS
K389 DTSCLFDKLKKEPDA
K389 DTSCLFDKLKKEPDA
K391 SCLFDKLKKEPDALT
K391 SCLFDKLKKEPDALT
S450 LNINLAMSPLPSSET
S454 LAMSPLPSSETPKPL
T457 SPLPSSETPKPLRSS
S464 TPKPLRSSADPALNQ
K476 LNQEVALKLESSPES
K476 LNQEVALKLESSPES
K545 SDMVNVFKLELVEKL
K545 SDMVNVFKLELVEKL
K551 FKLELVEKLFAEDTE
K560 FAEDTEAKNPFSTQD
T568 NPFSTQDTDLDLEML
Y578 DLEMLAPYIPMDDDF
S589 DDDFQLRSFDQLSPL
S652 DIKILIASPsStQVP
S654‑p KILIASPsStQVPQE
T656‑p LIASPsStQVPQETT
T662 StQVPQETTTAKASA
T663 tQVPQETTTAKASAY
T664 QVPQETTTAKASAYS
A667 QETTTAKASAYSGTH
S668 ETTTAKASAYSGTHS
S679 GTHSRTASPDRAGKR
K685 ASPDRAGKRVIEQTD
K685 ASPDRAGKRVIEQTD
S698 TDKAHPRSLNLSATL
S702 HPRSLNLSATLNQRN
N706 LNLSATLNQRNTVPE
T710 ATLNQRNTVPEEELN
K719 PEEELNPKTIASQNA
K719 PEEELNPKTIASQNA
S737 RKMEHDGSLFQAAGI
S770 KRVKGFISSEQNGTE
S771 RVKGFISSEQNGTEQ
T806 ESGLPQLTSYDCEVN
S819 VNAPIQGSRNLLQGE
  rat

 
K10 GAGGENEKKKMSSER
K10 GAGGENEKKKMSSER
K11 AGGENEKKKMSSERR
K12 GGENEKKKMSSERRK
K19 KMSSERRKEKSRDAA
K21 SSERRKEKSRDAARS
S31 DAARSRRSKESEVFY
K32 AARSRRSKESEVFYE
T63 KASVMRLTISYLRVR
Y66 VMRLTISYLRVRKLL
K71 ISYLRVRKLLDAGDL
I80 LDAGDLDIEDEMKAQ
S113 DGDMIYISDNVNKYM
K185 RGRTMNIKSATWKVL
K185 RGRTMNIKSATWKVL
S247 KTFLSRHSLDMKFSY
K289 LDSDHLTKTHHDMFT
K297 THHDMFTKGQVTTGQ
K377 KMTQLFTKVESEDTS
K389 DTSCLFDKLKKEPDA
K389 DTSCLFDKLKKEPDA
K391 SCLFDKLKKEPDALT
K391 SCLFDKLKKEPDALT
S450 LNINLAMSPLPASET
A454 LAMSPLPASETPKPL
T457 SPLPASETPKPLRSS
S464 TPKPLRSSADPALNQ
K476 LNQEVALKLESSPES
K476 LNQEVALKLESSPES
K531 SDMVNVFKLELVEKL
K531 SDMVNVFKLELVEKL
K537 FKLELVEKLFAEDTE
K546 FAEDTEAKNPFSAQD
T554 NPFSAQDTDLDLEML
Y564 DLEMLAPYIPMDDDF
S575 DDDFQLRSFDQLSPL
S641 DIKILIASPPSTQVP
P643 KILIASPPSTQVPQE
T645 LIASPPSTQVPQEMT
M651 STQVPQEMTTAKASA
T652 TQVPQEMTTAKASAY
T653 QVPQEMTTAKASAYS
A656 QEMTTAKASAYSGTH
S657 EMTTAKASAYSGTHS
S668 GTHSRTASPDRAGKR
K674 ASPDRAGKRVIEKTD
K674 ASPDRAGKRVIEKTD
S687 TDKAHPRSLNLSVTL
S691 HPRSLNLSVTLNQRN
N695 LNLSVTLNQRNTVPE
T699 VTLNQRNTVPEEELN
R708 PEEELNPRTIALQNA
R708 PEEELNPRTIALQNA
S726 RKMEHDGSLFQAAGI
S759 KRVKGYISSEQDGME
S760 RVKGYISSEQDGMEQ
T795 ESGLPQLTSYDCEVN
S808 VNAPIQGSRNLLQGE
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.